RVPH — Reviva Pharmaceuticals Holdings Income Statement
0.000.00%
Last trade - 00:00- $40.52m
- $27.50m
Annual income statement for Reviva Pharmaceuticals Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 February 29th | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.725 | 10.1 | 28.2 | 39.5 | 30.8 |
| Operating Profit | -0.725 | -10.1 | -28.2 | -39.5 | -30.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.618 | -8.52 | -28.2 | -39.2 | -29.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.618 | -8.52 | -28.3 | -39.3 | -29.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.618 | -8.52 | -28.3 | -39.3 | -29.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.618 | -8.52 | -28.3 | -39.3 | -29.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.237 | -0.576 | -1.45 | -1.65 | -0.903 |